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The chemokine CXCL16 plays an important role in the
recruitment of leukocytes to sites of inflammation influencing
the course of experimental glomerulonephritis. Here we
show that human kidneys highly express CXCL16 in the distal
tubule, connecting tubule and principal cells of the collecting
duct with weak expression in the thick ascending limb of
Henle. Beside the membrane localization, a soluble form of
CXCL16 can be proteolytically released which acts as a
chemotactic factor. In human renal tissue the expression
pattern of the disintegrin-like metalloproteinase ADAM10 is
similar to that of CXCL16, suggesting ADAM10 can
potentially cleave CXCL16 in vivo. When we tested this in
primary tubular cells we found that blockade of ADAM10
activity inhibited the IFN-c induced release of soluble
CXCL16. Acute tubular damage in renal allografts was
associated with elevated urinary CXCL16 and this correlated
with focally increased apical CXCL16 expression in the distal
tubules and collecting ducts. Renal allograft biopsies, with a
histopathological diagnosis of acute interstitial rejection,
showed increased basolateral ADAM10 expression together
with high numbers of infiltrating T cells. Our results suggest
that CXCL16 and ADAM10 are involved in the recruitment of
T cells to the kidney and play an important role in
inflammatory kidney diseases.
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The infiltration of leukocytes into sites of tissue damage is a
characteristic feature of an inflammatory process. It is well
established that chemokines are critical for this recruitment
of specific leukocyte subsets.1 The majority of chemokines are
secreted as small, soluble molecules. In contrast to these
secretory molecules, two chemokines, CXCL16 and fractalk-
ine/CX3CL1, are anchored in the cell membrane.2,3 Recently
an important role of CXCL16 in the development of kidney
diseases has been described. For instance, blocking of
CXCL16 by specific antibodies ameliorated experimental
immune nephritis in mice.4 In addition, CXCL16 played a
major role in the acute inflammatory or progressive phase of
established glomerulonephritis in rats.5 Blocking antibodies
against CXCL16 significantly attenuated monocyte/macro-
phage infiltration and glomerular injury in an anti-glomer-
ular basement membrane model.5
As a surface-expressed molecule, CXCL16 can function as
a scavenger receptor for phosphatidylserine and oxidized
lipoproteins and, thereby, enhance the uptake of oxidized
low-density lipoproteins.6 Beside this, CXCL16 can also exist
as a soluble molecule, inducing chemotaxis of CXCR6-
expressing T, natural killer, and natural killer T cells to
sites of inflammation and injury.7 Soluble CXCL16 is
generated from the cell surface by a process called
ectodomain shedding. The most prevalent protease for the
constitutive CXCL16 shedding is the disintegrin-like metal-
loproteinase ADAM10.8,9
Very few data exist about the expression of CXCL16 and
ADAM10 in the human kidney and their role in renal disease
progression. In this study, we have analyzed the expression of
ADAM10 and CXCL16 in the normal human kidney. We
demonstrate that ADAM10 and CXCL16 are constitutively
expressed and colocalize in renal tubular cells of distal
convoluted tubule (DCT), the connecting tubule (CNT), and
in cells of the collecting duct (CD). In addition, using a
specific metalloproteinase inhibitor and small interfering
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RNA (siRNA) experiments against ADAM10, we present
evidences that ADAM10 is involved in the interferon-g (IFN-
g)-induced cleavage of CXCL16 in Thick Ascending Limb of
Henle’s Loop and Early Distal Tubular Cells (TALDCs).
Notably, targeting ADAM10 and CXCL16 with siRNAs in
primary TALDC reduced chemotaxis of CXCR6-positive T
cells, suggesting that ADAM10 and CXCL16 are involved in
the recruitment of immune cells in inflammatory processes
in the kidney. Furthermore, we were able to detect elevated
levels of urinary CXCL16 in kidney allograft recipients
mirrored by focally increased apical expression of CXCL16 in
the distal tubules and CDs of allograft biopsies. Additionally,
in biopsies of patients with diagnosis of acute interstitial
rejection, we found enhanced basolateral ADAM10 expres-
sion in distal renal tubuli, which was associated with an
increased infiltration of T cells. In summary, our data suggest
that ADAM10 and CXCL16 may play important roles during
the process of renal inflammatory diseases such as acute
allograft rejection and may be useful targets for therapeutic
intervention.
RESULTS
CXCL16 is mainly expressed in segment-specific cells of DCT,
CNT and CD of normal human kidney
To investigate the in vivo expression of CXCL16 in the human
kidney, we analyzed serial sections of normal renal tissue by
immunohistochemistry. As shown in Figure 1a, in the renal
cortex and outer stripe, constitutive expression of CXCL16
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Figure 1 | CXCL16 localization in human kidney sections of healthy parts of tumor nephrectomies. (a) In the overview, CXCL16 protein
is constitutively expressed in tubular cells of the healthy kidney. Paraffin-embedded sections of normal human renal tissue were stained
with a polyclonal antibody against CXCL16. (b) Renal tissue stained with rabbit isotype IgG antibody was negative. Immunohistochemical
analysis of serial paraffin-embedded sections of normal renal tissue revealed its expression in the kidney cortex in the CD (c); in distal
convoluted tubules, connecting tubules, and the initial parts of cortical CDs (d), and in the TAL of Henle’s loop (e), as shown by
colocalization of CXCL16 with aquaporin-2 (f), calbindin D-28K (g), and Tamm Horsfall glycoprotein (h), respectively, in the same nephron
segments (examples are indicated by arrows). Note, that the proximal tubule was devoid of any signal for CXCL16. (i) Double
immunofluorescent staining of CXCL16 and aquaporin-2 in a cortical CD. CXCL16 expression (green) is detected in many aquaporin-2-
positive (red) principal cells of the CD; examples are marked with asterisks. In contrast, arrows indicate cells negative for either aquaporin-2
or CXCL16, thus representing presumably intercalated cells. (j) CXCL16 expression is not present in the intercalated cells. Double staining
with antibodies against carbonic anhydrase II (CAII, a marker for intercalated cells, red fluorescence) and CXCL16 (green fluorescence)
demonstrates that intercalated cells (arrows) do not express CXCL16, since both signals do not colocalize.
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was found in tubular cells. Weak expression of CXCL16 was
also seen in the glomeruli of the kidney. To confirm the
specificity of CXCL16 immunostaining, we used a rabbit
isotype control antibody, which did not show any immuno-
reactivity (Figure 1b). Using antibodies against aquaporin-2
(a marker protein for the CD), calbindin D-28K (a marker
protein for distal convoluted tubules, connecting tubules and
early parts of cortical CDs), and Tamm–Horsfall Glycoprotein,
expressed in the TAL, we can show that CXCL16 was
constitutively expressed in the CD (Figure 1c and f), in distal
convoluted cells, in connecting tubules (Figure 1d and g), and
a weak expression of CXCL16 was also found in the cortical
TAL cells (Figure 1e and h). No CXCL16 expression was
found in the proximal tubules. In the outer medulla, CXCL16
was expressed in CDs but not in TAL cells. In detail, we
identified the segment-specific cells of DCT, CNT, and CD as
the CXCL16-expressing cells. Double immunofluorescence
using antibodies against aquaporin-2 (as a marker for
principal cells in the CD) and CXCL16 demonstrated CXCL16
expression in the principal cells of the CD (Figure 1i). Vice
versa, no CXCL16 expression was seen in intercalated cells, as
shown with double staining experiments with anti-carbonic
anhydrase II and CXCL16 antibodies (Figure 1j).
ADAM10 is involved in the IFN-c induced release of CXCL16
in primary TALDC
It is known that transmembrane CXCL16 can be cleaved by
ADAM10, and the soluble form of CXCL16 can act as a
chemoattractant for immune cells.9 To characterize the
metalloproteinase responsible for the shedding of CXCL16,
we analyzed the supernatants of primary human renal
TALDCs using a specific CXCL16 enzyme-linked immuno-
sorbent assay (ELISA). As shown in Figure 2a, IFN-g induced
approximately a twofold increase in the release of
CXCL16. The ADAM10-specific metalloproteinase inhibitor,
GI254023X, and the broad-spectrum metalloproteinase
inhibitors, GM6001 and TAPI-2, blocked the IFN-g-stimu-
lated release of CXCL16 (Figure 2a). To confirm this result,
we also analyzed cell-surface-bound CXCL16. As expected,
inhibition of metalloproteinases increased the level of cellular
CXCL16 as shown by western blot analysis (Figure 2b) and
CXCL16-specific ELISA (Figure 2d). With siRNA against
CXCL16, both bands were significantly reduced, verifying the
specificity of the CXCL16 antibody used in our western blot
analysis. Furthermore, using ADAM10 siRNA, we were able
to very efficiently knock down the expression of ADAM10
protein in primary TALDCs (Figure 2e). The amount of
soluble CXCL16 was significantly decreased in the super-
natant of ADAM10 siRNA-treated cells (Figure 2f), thus
confirming that ADAM10 is involved in the IFN-g-stimu-
lated cleavage of CXCL16 in TALDCs.
ADAM10 is constitutively expressed in the segment-specific
cells of the DCT, CNT, and CD in the human kidney
To prove that ADAM10 may also be the potential protease
cleaving CXCL16 in tubular cells in vivo, we analyzed the
expression of ADAM10 in the human kidney. In the renal
cortex, ADAM10 was constitutively expressed in tubular
profiles, and weakly in scattered glomerular cells (Figure 3a).
Constitutive ADAM10 expression could be observed in the
DCT and CNT (Figure 3c and f), CD (Figure 3b and e), and a
weaker expression was found in cells of the cortical TAL
(Figure 3d and g). However, the expression level seemed to be
roughly stronger than it was for CXCL16 in the hitherto
mentioned nephron segment. To again separate intercalated
cells from segment-specific cells, double labeling with specific
antibodies for detection of principal (aquaporin-2) and
intercalated cells (Hþ -ATPase) were performed. This allowed
us to identify principal cells as ADAM10-expressing cells in
the CD (Figure 3h). Intercalated cells did not express
ADAM10 (Figure 3i). Importantly, confocal analysis revealed
that ADAM10 and CXCL16 are constitutively expressed in
the same tubular cells (Figure 3j).
Blocking soluble CXCL16 with siRNAs against ADAM10 and
CXCL16 decreases the chemotaxis of CXCR6-expressing
T cells
The recruitment of leukocytes into the kidney has emerged as
a key event in the development of inflammatory kidney
diseases.10 The only known receptor of CXCL16 is CXCR6.
CXCR6 is expressed on CD4-positive effector memory T-cell
subsets and natural killer T cells.11,12 Using fluorescence-
activated cell sorting analysis, we confirmed that Jurkat
T cells express transmembrane CXCR6 (Figure 4a). Using
siRNAs against CXCL16 and ADAM10 we could reduce the
release of CXCL16 from tubular cells (Figure 4b). In IFN-g-
treated tubular cells, ADAM10 inhibition reduced the
amount of soluble CXCL16 to almost constitutive levels. In
contrast, CXCL16 knockdown completely abolished the
release of CXCL16 (Figure 4b). Soluble CXCL16 is known
to recruit CXCR6-expressing cells to sites of inflammation.12
To investigate the role of soluble CXCL16 released by
TALDCs in this recruitment process, we performed chemo-
taxis assays using supernatants from siRNA-transfected
TALDCs (Figure 4b). As shown in Figure 4c, employment
of supernatants of TALDC-treated with CXCL16 and
ADAM10 siRNA reduced the chemotaxis of T cells. Note,
the strongest effect was seen with supernatants of ADAM10
siRNA-treated TALDCs.
Differential expression of CXCL16 and ADAM10 in
transplanted kidneys with ATN and IR and determination
of urinary CXCL16 levels
To investigate the involvement of ADAM10 and CXCL16
in the recruitment of T cells in biopsies of kidneys of
transplanted patients, we analyzed in a pilot study the
distribution of ADAM10 and CXCL16 in 11 kidney
transplanted patients diagnosed with acute interstitial rejec-
tion (IR) or acute renal tubular damage as controls with
double immunofluorescence. IR served as an example for
inflammatory processes in the human kidney, where infiltra-
tion of T cells is the major component.13
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The clinical characteristics together with CXCL16 and
ADAM10 expression pattern of the patient’s biopsies are
summarized in Tables 1 and 2. In all acute tubular necrosis
(ATN) patients, after renal transplantation, expression of
CXCL16 was increased in a focal manner on the apical side of
distinct tubuli in comparison with normal kidneys (Figure 5a
and b), whereas ADAM10 expression was not changed
significantly (Figure 5b). The strong apical expression of
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Figure 2 | Influence of metalloproteinases on the expression and release of CXCL16. (a) Analysis of soluble CXCL16 released from
primary TALDCs with a CXCL16-specific ELISA. Cells were preincubated with different proteinase inhibitors for 15 min before IFN-g
(24 ng/ml) was added for 24 h. Application of IFN-g (24 ng/ml) increased the amount of soluble CXCL16 in the supernatants of TALDCs.
The ADAM10-specific metalloproteinase inhibitor, GI254023X (GI), and the broad-spectrum metalloproteinase inhibitors, GM6001 and
TAPI-2, reduced the IFN-g-induced CXCL16 release. Data are mean±s.d. (n¼ 3); ***Po0.001 versus control; ###Po0.001, ##Po0.01; #Po0.05
versus cytokine-treated cells. (b) Inhibition of metalloproteinases increased cellular CXCL16 protein expression in TALDCs. Fifteen minutes
before application of IFN-g, cells were pretreated with the indicated concentration of the metalloproteinase inhibitors GI254023X, GM6001,
and TAPI-2. CXCL16 protein levels were measured by western blot analysis and b-actin was used as a loading control. (c) Knockdown of
CXCL16 with CXCL16-specific siRNA in TALDCs is shown by western blot analysis. (d) Application of pharmacological inhibitors of
metalloproteinases increased the amount of cellular CXCL16. Cell lysates were isolated as described under Materials and Methods, and 15 mg
total proteins were used to measure the amount of cell-expressed CXCL16 by CXCL16-specific ELISA. Data are meanþ s.d. (n¼ 5).
Statistically significant release of CXCL16 (Po0.001) is indicated by asterisk. (e) Suppression of ADAM10 protein levels by RNA interference
in the presence and absence of IFN-g. Cell lysates of TALDCs were prepared 48 h after transfection with siRNA specific for ADAM10 and an
unspecific siRNA. Mock-transfected cells treated with the transfection lipid in the absence of siRNA were used as a control. Western blot
analysis of ADAM10 protein expression was performed. Blots were reprobed with an antibody specific for b-actin as a loading control.
(f) Inhibition of ADAM10 by siRNA reduced the IFN-g-stimulated CXCL16 release in TALDCs. Supernatants of siRNA-treated and IFN-g-
stimulated or unstimulated cells were analyzed for soluble CXCL16 using a CXCL16-specific ELISA (n¼ 3); ***Po0.001 versus control;
###Po0.001 versus IFNg-treated cells.
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CXCL16 correlated with elevated urinary CXCL16 levels
(Table 1). In contrast, in healthy volunteers only weak
amounts of urinary CXCL16 could be detected (Figure 5c).
In addition, compared with normal renal tissue and ATN,
we detected stronger distal tubular ADAM10 expression in all
allograft biopsies with the diagnosis of IR (Figure 6; Table 2).
Importantly, in one patient (Figure 6, patient B1), who had
the highest level of infiltrating T cells (Table 2), very strong
tubular ADAM10 (Figure 6, arrows) expression was observed
along with decreased or no CXCL16 expression in the same
tubuli (Figure 6, arrows). Interestingly, in some distal tubuli
of another patient (Figure 6, patient B5) strong expression
and colocalization of ADAM10 and CXCL16 could be
detected (Figure 6, patient B5). In summary, in all kidney
transplant patients with IR, increased tubular ADAM10
expression and variable CXCL16 expression could be
observed, which was paralleled by high levels of infiltrating
T cells. Moreover, less pronounced amounts of urinary
CXCL16 were measured at the time of IR (Figure 5c).
DISCUSSION
The migration of leukocytes through vessels and beyond the
vascular compartment is dependent in part on small
chemoattractant proteins called chemokines. Leukocyte
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Figure 3 | Localization of ADAM10 protein in normal human kidney. (a) In the overview, ADAM10 protein is mainly expressed in tubular
cells, but expression was also found in glomerular cells. Serial sections of normal renal tissue represented constitutive ADAM10 expression
in aquaporin-2 (e), calbindin D-28K (f), and Tamm–Horsfall glycoprotein (g) expressing tubular profiles, which correspond to CD, (DCT, CNT),
and TAL, respectively. Proximal tubules were devoid of any specific ADAM10 staining. (h) Immunofluorescent detection of ADAM10
(red fluorescence) in aquaporin-2-positive principal cells of the CD (green fluorescence). A prominent overlap of both signals in the same
cells can be seen, indicated in the examples by asterisks. In contrast, arrows indicate cells negative for either aquaporin-2 or ADAM10,
thus representing presumable intercalated cells. (i) ADAM10 is not expressed in the intercalated cells of the CD. Note: arrows represent
Hþ -ATPase-expressing intercalated cells (green colour) that do not express ADAM10 (red colour); compare with the merged view.
(j) Confocal immunofluorescence analysis of ADAM10 and CXCL16 expression in a cortical CD. Tissue section was stained with Alexa Fluor
488 and Cy3 secondary antibodies to visualize the localization of CXCL16 (red) and ADAM10 (green) proteins, respectively. Both signals
can be confined to same segment-specific cells; see merged picture on the right.
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Figure 4 | Supernatants from ADAM10- and CXCL16 siRNA-transfected TALDCs decreased the chemotaxis of Jurkat T cells.
(a) Surface expression of the chemokine receptor CXCR6 in Jurkat T cells analyzed by fluorescence-activated cell sorting analysis.
(b) Inhibition of CXCL16 protein expression by siRNA fully abolished release of CXCL16 in TALDCs. Cells were transfected with different
siRNA duplexes for inhibition of ADAM10 or CXCL16, an unspecific siRNA (scrambled), or not transfected with siRNA (mock). A total of 24 h
after transfection, TALDCs were stimulated with IFN-g for 24 h, where indicated, and supernatants were collected. Soluble CXCL16 was
determined by a CXCL16-specific ELISA (n¼ 4). Data are mean±s.d.; ***Po0.001 versus control; ###Po0.001 versus IFN-g-treated cells.
(c) Decrease of soluble CXCL16 correlates with a reduction in the migration of Jurkat T cells. Supernatants shown in Figure 5b were used
for chemotaxis assays (n¼ 2). Recombinant CXCL16 induced migration of CXCR6-expressing Jurkat T cells about threefold; **Po0.01;
*Po0.05 versus control.
Table 1 | Clinical features and CXCL16 and ADAM10 analysis in ATN patients with renal biopsy
Case Gender Age
Days after
TX
Serum
creatinine
(mg/dl)
Creatinine
clearance
(ml/min/1.73 m2)
Urinary
CXCL16
(pg/ml)
T cells Tub.
Int. cells/HPF
Focally apical
tubular CXCL16
expression
Basolateral
tubular ADAM10
expression
A1 M 52 21 1.65 44 651 23.8 +++ +
A2 F 65 25 3.7 33 441 18.1 +++ +
A3 F 61 29 3.1 15.3 468 26.8 ++ ++
A4 M 65 15 2.9 21.9 1,209 20.1 +++ +
A5 M 62 33 2.5 39.7 428 5.2 +++ +
A6 M 27 12 6.0 11.3 122 8.4 ++ +
+, intensity of CXCL16 or ADAM10 expression in comparison with that in normal kidney; ATN, acute tubular necrosis; HPF, high-power field; Tub. Int., tubular interstitium; TX,
transplantation.
Table 2 | Clinical features and CXCL16 and ADAM10 analysis in IR patients with renal biopsy
Case Gender Age
Days after
TX
Serum
creatinine
(mg/dl)
Creatinine
clearance
(ml/min/1.73 m2)
Urinary
CXCL16
(pg/ml)
T cells Tub.
Int. cells/HPF
Mean tubular
CXCL16
expression
Basolateral
tubular ADAM10
expression
B1 M 63 90 2.15 31.2 137 131.3  +++
B2 M 34 32 1.62 49 91 78.1  +++
B3 M 45 36 3.7 17.9 473 62.2  ++
B4 M 71 22 3.2 19.2 91 73.8  ++
B5 F 43 20 2.1 23.1 444 59.2 ++ +++
, decreased expression of CXCL16 as compared with normal CXCL16 expression; +, intensity of ADAM10 expression in comparison with that in normal kidney; HPF, high-
power field; IR, interstitial rejection; Tub. Int., tubular interstitium; TX, transplantation.
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traffick from the peripheral blood into the tubulointerstitial
compartment of the kidney is a hallmark of almost any kind
of renal inflammatory disease. Interestingly, some chemo-
kines are known to be expressed constitutively, whereas
proinflammatory chemokines are exclusively expressed in
response to specific stimuli. For instance, the transmembrane
chemokine, CXCL16, is known to be expressed in epithelial
cells, like keratinocytes, in the absence of inflammatory
activators.14 In this study, we could show, for the first time,
constitutive expression of CXCL16 in distal tubular cells in
normal human renal tissue. In a mouse model of experi-
mental immune nephritis, increased CXCL16 expression was
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Figure 5 | Increased urinary CXCL16 correlated with focally apical CXCL16 expression in tubular cells of renal allografts with
the histopathological diagnosis of ATN. Six allograft biopsies of patients diagnosed with ATN (cases A1–A6; clinical parameters and
CXCL16 analysis are shown in Table 1) were analyzed by CXCL16 immunohistochemical analysis (a–f) and with ADAM10 (green colour) and
CXCL16 (red colour) double immunofluorescence staining (g–l). Notably, all patients showed focally increased apical CXCL16 expression in
renal tubuli. Strongest apical CXCL16, seen in patient A4 (d), correlated with the highest amount of urinary CXCL16 (Table 1). In contrast,
ADAM10 expression (green colour) was not significantly changed in ATN patients (A1–A6) compared with normal kidney (g–l). (m) Urinary
CXCL16 measured by a CXCL16-specific ELISA in healthy volunteers (normal), in patients with IR, and in patients with ATN. Data are
mean±s.d.; **Po0.01 versus control.
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found in the glomeruli, tubules, and in the vascular
endothelium.4 In vitro studies identified lipopolysaccharide-
stimulated mesangial cells as a rich source of the chemokine
CXCL16.4 Our immunohistochemical analysis of normal
human renal tissue identified tubular cells as the main
CXCL16-expressing cells. Specifically, CXCL16 expression
was identified in segment-specific cells of the DCT, CNT,
cortical CD, and in the TAL, but not in intercalated cells.
Different hypotheses can be presented concerning the role of
the constitutive expression of CXCL16 in tubular cells.
Membrane-bound CXCL16 is known to mediate adhesion
and phagocytosis of Gram-negative and Gram-positive
bacteria. Notably, CXCL16 is not only able to trigger
phagocytosis of bacteria, but can also directly kill bacteria.15
In humans, membrane-bound CXCL16 is expressed on
macrophages, monocyte-derived dendritic cells, and blood
myeloid dendritic cell.16 Dendritic cells can release CXCL16,
which acts as a chemoattractant molecule and recruits
CXCR6-expressing cells, like activated T cells and natural
killer cells, to sites of inflammation. In this study, we were
able to show that primary TALDC increased levels of soluble
CXCL16 after IFN-g treatment. Therefore, also in the kidney,
this increased release of CXCL16 could play an important
role in the recruitment of T cells during inflammation to sites
of kidney injury.
In our study, we could show that in primary TALDCs
ADAM10 is involved in processing of CXCL16. A specific
ADAM10 metalloproteinase inhibitor, as well as siRNA
against ADAM10, efficiently blocked the IFN-g-induced
cleavage of CXCL16 in TALDCs. Interestingly, in fibroblasts
and endothelial cells, ADAM10 has been implicated in
constitutive shedding of CXCL16,8,9 whereas ADAM17 seems
to be involved in the phorbol-ester-induced shedding of the
chemokine. Using primary TALDCs, we could demonstrate
that IFN-g induced a more than fourfold increase in the
shedding of CXCL16. Only ADAM10 siRNA could signifi-
cantly inhibit the IFN-g-induced CXCL16 shedding in
TALDC, whereas ADAM17 siRNA had only a marginal effect
(data not shown). Furthermore our study provides in vivo
evidence that ADAM10 is localized like CXCL16 in the
segment-specific cells of the distal nephron and CD, but not
in intercalated cells, presuming that ADAM10 is also in vivo
the proteinase cleaving CXCL16.
It is well established that soluble CXCL16 acts as a
chemoattractant for CXCR6-expressing immune cells.3,12
With CXCL16- and ADAM10-knockdown experiments in
TALDCs, we were able to underline the importance of
ADAM10 and soluble CXCL16 in the recruitment of T cells.
Importantly, in renal allograft biopsies of patients with acute
interstitial rejection, we found increased tubular ADAM10
expression, which correlated with high numbers of infiltrat-
ing T cells. Together with our ADAM10-knockdown experi-
ment in TALDCs, which reduced the chemotaxis of T cells
below basal levels, we can speculate that ADAM10, beside
CXCL16 ADAM10 Merge
Normal kidney
Patient B1
Patient B5
Figure 6 | Increased ADAM10 expression in allograft biopsies of kidney transplant patient with the clinical and histopathological
diagnosis of acute IR. Renal allograft biopsies of patients diagnosed with IR were analyzed by double immunofluorescence for ADAM10
and CXCL16 expression in comparison with normal kidney (upper panel). Clinical features and ADAM10 analysis of patients are listed in
Table 2. Tissue sections were stained with Alexa Fluor 488 and Cy3 secondary antibodies to visualize the localization of CXCL16 (red)
and ADAM10 (green) proteins, respectively. In some tubuli of patient B1 (marked with arrows), strong basolateral ADAM10 expression
and no CXCL16 expression could be seen (middle panel). In contrast, in few tubuli of the same patient (marked with a star) both
molecules colocalized. In the lower panel (patient B5), strong coexpression of ADAM10 and CXCL16 in a tubule is visible, accompanied
with interstitial inflammatory infiltrates.
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CXCL16, is an attractive new target molecule for treatment of
renal inflammatory processes. Of note, in biopsy-proven IR,
increased ADAM10 expression (Figure 6, arrows) was
encountered with variable CXCL16 expression, including
decreased, focally absent or increased expression. The absent
or decreased tubular CXCL16 expression could be explained
by an increased shedding of CXCL16. This notion is
supported by two findings: first, we found that inhibition
of ADAM10 increased cellular CXCL16 (Figure 2b) in
TALDCs. Second, we were not able to detect soluble CXCL16
in western blot analysis using the same CXCL16 antibody
used in immunohistochemistry, assuming that this antibody
does not detect the cleaved form of CXCL16.
Recently, in patients with lupus nephritis the levels of
urinary CXCL16 showed superior specificity and sensitivity
in distinguishing subjects with active renal disease.17 We
found elevated levels of urinary CXCL16 in kidney transplant
patients with ATN and in patients with IR, who were
paralleled by a focally increased apical CXCL16 expression in
renal tubuli in ATN patients and an increased basolateral
ADAM10 expression of distal tubuli in IR patients. Never-
theless, to determine whether urinary CXCL16 could be a
useful biomarker to monitor tubular kidney injury events,
ELISA-based studies in larger groups of patients are required.
In summary, we have characterized, for the first time, the
in vivo expression of ADAM10 and CXCL16 in normal renal
tissue. We also have provided preliminary results on the
expression of these molecules in renal allograft biopsies of
kidney transplant patients with ATN and IR. In IR patients,
strong basolateral tubular ADAM10 expression and variable
CXCL16 expression accompanied with high numbers of
infiltrating T cells was the most interesting finding. In
contrast, in ATN patients, basolateral ADAM10 expression
was not significantly changed. Therefore, we assume that
in IR patients ADAM10 and CXCL16 play an important role
in the recruitment of T cells. As we can only speculate that
the decreased CXCL16 expression as observed in patient B1
(Figure 6) is due to downregulation of CXCL16 or increased
shedding of the chemokine, further analysis in animal models
of kidney transplantation should be performed. Using such
models, inhibition of CXCL16 and ADAM10 by blocking
antibodies and siRNA will provide new data concerning the
role of both molecules in rejection processes of transplanted
kidneys. Taken this data together, we speculate that targeting
of ADAM10 and CXCL16 might offer a new attractive
strategy to prevent recruitment of T cells during acute
rejection. Future studies will make evident the importance of
ADAM10 and CXCL16 in the transplanted human kidney
and in inflammatory kidney diseases.
MATERIALS AND METHODS
Kidney sections
Specimens were taken from healthy parts of renal tissue from six
different tumor nephrectomies (obtained from two female and four
male patients with ages ranging from 34 to 66 years). Kidney tissues
were originally submitted for diagnostic purposes and studied in
accordance with national and local ethical principles. The use of
human tissue samples has been approved by the local ethical
committee (ref. no. #11/10/04). Tissue sections of renal allograft
biopsies, which were not needed for diagnostic evaluation, were
obtained from the Department of Cellular and Molecular Pathology,
German Cancer Research Center, Heidelberg, Germany.
Urine samples
Freshly obtained first-morning urine after initial void was collected
in a standardized manner from patients after renal transplantation.
Immediately, urine samples were spun at 4 1C at 2,000 g and three to
five aliquots were prepared. After determination of urinary
creatinine and total urine protein level, samples were stored at
20 1C until soluble CXCL16 concentrations were detected by
ELISA. Urinary CXCL16 of 11 kidney transplant patients were
analyzed on the day of biopsy. Creatinine clearance of the patients
was calculated on the day of biopsy.
Isolation and culture of human renal tubular epithelial cells
Human renal tubular epithelial cells were separated using antibody-
coated magnetic beads as previously described.18 Primary TALDCs
were characterized as previously described19 and were seeded in six-
well plates pre-coated with human collagen IV and fetal calf serum.
siRNA
For downregulation of endogenous CXCL16 and ADAM10 expres-
sion, the following siRNA duplexes (MWG Biotech AG, Ebersberg,
Germany) were used: CXCL16 construct, 50-CAUGAAUCGUCU
CCGGAAACATT-30; ADAM10 construct, 50-AGACAUUAUGAAGG
AUUAUTT-30. As a negative control an unspecific scrambled siRNA
duplex (50-AGGUAGUGUAAUCGCCUUGTT-30) was used.
Transfection of siRNA
Twenty-four hours before transfection, 5 104 cells were seeded in
six-well plates. Transfection of siRNA was performed using
Oligofectamine (Invitrogen, Karlsruhe, Germany) and 10 nM siRNA
duplexes (MWG Biotech AG) per well. Transfection was performed
as previously described.20 All cells were assayed 24–72 h after the
transfection procedure. Specific silencing of targeted genes was
confirmed by at least two independent experiments using western
blot analysis. Conditioned media were harvested and analyzed by
ELISA for the presence of released CXCL16.
Cytokines, antibodies, and chemicals
Recombinant human CXCL16, recombinant human IFN-g,
anti-human ADAM10 ectodomain antibody, and anti-human
CXCR6 antibody were obtained from R&D Systems (Wiesbaden,
Germany). Rabbit CXCL16 (western blot, immunohistochemistry,
immunofluorescence) was from Peprotech (London, UK). The
rabbit anti-calbindin D-28K (EG-20) and anti-aquaporin-2
antibody (immunohistochemistry and immunofluorescence) were
obtained from Sigma (Taufkirchen, Germany). The polyclonal
ADAM10 antibody (for immunohistochemistry) was from Chemi-
con (Hampshire, UK) and the polyclonal ADAM10 antibody (for
western blotting) was from Calbiochem (Darmstadt, Germany). The
Tamm–Horsfall protein antibody for immunohistochemistry was
obtained from BIOTREND GmbH (Cologne, Germany). The Hþ -
ATPase antibody (sc-20943) and the carbonic anhydrase II antibody
(sc-48351) were from Santa Cruz Biotechnology (Heidelberg,
Germany). The monoclonal ADAM10 (mAb 11G2, for double
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immunofluorescence) to the ADAM10 ectodomain was from
Diaclone (Besancon, France). The ADAM10-specific metalloprotei-
nase inhibitor, GI254023X, was described before.21
CXCL16 cleavage assays
TALDCs were grown in complete medium in six-well dishes for 24 h.
The cells were washed with phosphate-buffered saline and 1 ml of
fetal calf serum-free medium, with or without metalloproteinase
inhibitor being added. After 10 min, cells were stimulated with
IFN-g (24 ng/ml) or left unstimulated for the indicated periods of
time. The conditioned media were harvested and cleared by
centrifugation. The presence of soluble CXCL16 in the conditioned
media was quantified by a CXCL16-specific ELISA (PeproTech).
CXCL16-specific ELISA
The ELISA for human CXCL16 was conducted using Microlon
96-well plates (Greiner, Nurtingen, Germany) at room temperature,
the reaction volume being 100 ml. The human CXCL16 ELISA
Development kit from Peprotech was used according to the
manufacturer’s manual. All samples were tested in duplicates.
Western blot analysis
Cell extracts were prepared at the indicated time points as described
previously.22 Proteins were separated under reducing conditions by
electrophoresis on 10 or 12% SDS–polyacrylamide gel for detection of
ADAM10 or CXCL16, respectively. Separated proteins were trans-
ferred onto nitrocellulose membranes (Bio-Rad, Munich, Germany).
The blots were blocked for 30 min with 5% (w/v) non-fat dry milk
dissolved in TTBS (1TTBS: 20 mM Tris, 150 mM NaCl, pH 7.5, 0.1%
Tween-20). Blots were probed overnight with a polyclonal CXCL16
antibody or anti-ADAM10 antibody diluted in TTBS containing 2%
(w/v) non-fat dry milk. After incubation for 30 min with horseradish
peroxidase-conjugated secondary antibody (Santa Cruz Biotechno-
logy), blots were developed with an enhanced chemiluminescence
system (Amersham, Munich, Germany) and exposed to Hyperfilm
enhanced chemiluminescence system (Amersham).
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinized in xylene,
rehydrated through a series of graded concentrations of ethanol, and
washed in 10 mM phosphate-buffered 150 mM saline, pH 7.4.
Antigen retrieval was performed by incubating the tissue sections
for 20 min in 0.01 M sodium citrate buffer, pH 6, in a microwave
oven (500 W). Tissue sections were treated with 3% H2O2 in
methanol for 30 min at room temperature. After blocking sections
with phosphate-buffered saline containing 10% horse serum and 1%
bovine serum albumin for 1 h, they were incubated with an avidin/
biotin blocking kit (Linaris, Wertheim, Germany) following the
manufacturer’s protocol. The serial sections were incubated over-
night at 4 1C with primary antibodies as indicated. After washing the
slides, the Universal Quick kit (Linaris) was used to stain the kidney
sections. As a substrate, the AEC Substrate kit from BioGenex (San
Ramon, CA, USA) was used to detect the immune complexes. Slides
were counterstained with hematoxylin (Roth, Karlsruhe, Germany).
The sections were inspected with a Zeiss microscope coupled to a
12-bit digital image camera.
Fluorescence microscopy
For immunofluorescence analysis, tissue sections were deparaffi-
nized as described above and antigen retrieval was performed by
incubating the tissue sections for 20 min in 0.01 M sodium citrate
buffer, pH 6, in a microwave oven (500 W). After incubation with
blocking buffer (0.1% Triton X-100/phosphate-buffered saline
containing 1% bovine serum albumin and 10% horse serum) for
1 h, tissue sections were incubated with the first antibodies (diluted
in 1% bovine serum albumin/10% horse serum/phosphate-buffered
saline/0.1% Triton X-100) as indicated. Following washing, bound
antibodies were detected using Alexa 488-conjugated goat anti-
mouse (Molecular Probes, Karlsruhe, Germany) or goat anti-rabbit
Cy3 (Molecular Probes) secondary antibodies. Nuclei were stained
with 40,6-diamidino-2-phenylindole (Sigma, Deisenhofen, Ger-
many) and slides were mounted in Fluoromount G (Southern
Biotechnology, Birmingham, AL, USA). Evaluation was performed
by fluorescence microscopy (Keyence, Neu-Isenburg, Germany) or
slides were analyzed with an LSM 510 confocal laser-scanning
microscope (Carl Zeiss, Jena, Germany).
Chemotaxis assay
The chemotaxis of Jurkat T cells in response to recombinant
CXCL16 or supernatants of siRNA-transfected primary TALDCs was
measured as described before,23 in which recombinant CXCL16
(100 ng/ml) or serum-free supernatants of siRNA-transfected
TALDCs were added to the lower chamber in a volume of 600 ml.
The plates were incubated for 2 h at 37 1C in 5% CO2. Migrated cells
were counted per visual field using inverted microscope at an
original magnification of  200 and the experiments were repeated
twice in triplicates.23
Statistical analysis
The number of experiments, which were performed either in
duplicate or triplicate, is reported in the legends to the figurers. Data
are presented by means±s.d. Statistical and significant differences
were determined by analysis of variance with Bonferroni’s multi-
comparison test.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We thank Nicole Ka¨mpfer-Kolb for excellent technical assistance.
This work was supported, in part, by DFG, FOR809, TP5, and by IZKF
Biomat. RWTH Aachen to AL.
REFERENCES
1. Campbell DJ, Kim CH, Butcher EC. Chemokines in the systemic
organization of immunity. Immunol Rev 2003; 195: 58–71.
2. Bazan JF, Bacon KB, Hardiman G et al. A new class of membrane-bound
chemokine with a CX3C motif. Nature 1997; 385: 640–644.
3. Matloubian M, David A, Engel S et al. A transmembrane CXC chemokine is
a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000; 1: 298–304.
4. Wu T, Xie C, Bhaskarabhatla M et al. Excreted urinary mediators in an
animal model of experimental immune nephritis with potential
pathogenic significance. Arthritis Rheum 2007; 56: 949–959.
5. Garcia GE, Truong LD, Li P et al. Inhibition of CXCL16 attenuates
inflammatory and progressive phases of anti-glomerular basement
membrane antibody-associated glomerulonephritis. Am J Pathol 2007;
170: 1485–1496.
6. Minami M, Kume N, Shimaoka T et al. Expression of SR-PSOX, a novel
cell-surface scavenger receptor for phosphatidylserine and oxidized
LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001;
21: 1796–1800.
7. Heydtmann M, Lalor PF, Eksteen JA et al. CXC chemokine ligand 16
promotes integrin-mediated adhesion of liver-infiltrating lymphocytes
to cholangiocytes and hepatocytes within the inflamed human liver.
J Immunol 2005; 174: 1055–1062.
Kidney International (2008) 74, 328–338 337
A Schramme et al.: Characterizing CXCL16 and ADAM10 in the normal and transplanted kidney o r i g i n a l a r t i c l e
8. Abel S, Hundhausen C, Mentlein R et al. The transmembrane
CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha
and shed by the activity of the disintegrin-like metalloproteinase
ADAM10. J Immunol 2004; 172: 6362–6372.
9. Gough PJ, Garton KJ, Wille PT et al. A disintegrin and metalloproteinase
10-mediated cleavage and shedding regulates the cell surface expression
of CXC chemokine ligand 16. J Immunol 2004; 172: 3678–3685.
10. Segerer S, Schlondorff D. Role of chemokines for the localization of
leukocyte subsets in the kidney. Semin Nephrol 2007; 27: 260–274.
11. Geissmann F, Cameron TO, Sidobre S et al. Intravascular immune surveillance
by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005; 3: e113.
12. Johnston B, Kim CH, Soler D et al. Differential chemokine responses and
homing patterns of murine TCR alpha beta NKT cell subsets. J Immunol
2003; 171: 2960–2969.
13. van der Woude FJ, Deckers JG, Mallat MJ et al. Tissue antigens in
tubulointerstitial and vascular rejection. Kidney Int Suppl 1995; 52:
S11–S13.
14. Scholz F, Schulte A, Adamski F et al. Constitutive expression and
regulated release of the transmembrane chemokine CXCL16 in human
and murine skin. J Invest Dermatol 2007; 127: 1444–1455.
15. Shimaoka T, Nakayama T, Kume N et al. Cutting edge: SR-PSOX/CXC
chemokine ligand 16 mediates bacterial phagocytosis by APCs through
its chemokine domain. J Immunol 2003; 171: 1647–1651.
16. Tabata S, Kadowaki N, Kitawaki T et al. Distribution and kinetics of
SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell
subsets and CD4+ T cells. J Leukoc Biol 2005; 77: 777–786.
17. Wu T, Xie C, Wang HW et al. Elevated urinary VCAM-1, P-selectin,
soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine
lupus strains and human lupus nephritis. J Immunol 2007; 179:
7166–7175.
18. Baer PC, Nockher WA, Haase W et al. Isolation of proximal and distal
tubule cells from human kidney by immunomagnetic separation.
Technical note. Kidney Int 1997; 52: 1321–1331.
19. Baer PC, Bereiter-Hahn J, Schubert R et al. Differentiation status of human
renal proximal and distal tubular epithelial cells in vitro: differential
expression of characteristic markers. Cells Tissues Organs 2006; 184:
16–22.
20. Elbashir SM, Harborth J, Lendeckel W et al. Duplexes of 21-nucleotide
RNAs mediate RNA interference in cultured mammalian cells. Nature
2001; 411: 494–498.
21. Ludwig A, Hundhausen C, Lambert MH et al. Metalloproteinase inhibitors
for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that
differentially block constitutive and phorbol ester-inducible shedding of
cell surface molecules. Comb Chem High Throughput Screen 2005; 8:
161–171.
22. Wiechen K, Sers C, Agoulnik A et al. Down-regulation of caveolin-1,
a candidate tumor suppressor gene, in sarcomas. Am J Pathol 2001;
158: 833–839.
23. Klawitter S, Hofmann LP, Pfeilschifter J et al. Extracellular nucleotides
induce migration of renal mesangial cells by upregulating
sphingosine kinase-1 expression and activity. Br J Pharmacol 2007;
150: 271–280.
338 Kidney International (2008) 74, 328–338
o r i g i n a l a r t i c l e A Schramme et al.: Characterizing CXCL16 and ADAM10 in the normal and transplanted kidney
